DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Chidamide is an investigational drug.
There have been 67 clinical trials for Chidamide. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Sun Yat-sen University, and Ruijin Hospital.
There are three US patents protecting this investigational drug and twenty-eight international patents.
Recent Clinical Trials for Chidamide
|Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer||First Affiliated Hospital, Sun Yat-Sen University||Phase 2|
|Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma||Hunan Cancer Hospital||Phase 2|
|Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Unfit for Conventional Chemotherapy||Ruijin Hospital||Phase 2|
Top disease conditions for Chidamide
Top clinical trial sponsors for Chidamide
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Chidamide||Start Trial||Histone deacetylase inhibitors||Orchid Chemicals & Pharmaceuticals Limited (Chennai, IN)||Start Trial|
|Chidamide||Start Trial||Crystal form of chidamide, preparation method and use thereof||SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (Shenzhen, Guangdong, CN)||Start Trial|
|Chidamide||Start Trial||Agents for killing HIV-1-infected cells and application thereof||KAGOSHIMA UNIVERSITY (Kogoshima-Shi, Kagoshima, JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Chidamide||European Patent Office||2205563||1989-12-31||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|